Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
BUSINESS
Takeda Files Liquid Formulation of IVIg Therapy in Japan
Takeda Pharmaceutical said on February 14 that it has submitted a new drug application for the intravenous immunoglobulin preparation Kenketu Glovenin-I 10% for IV Injection (polyethylene glycol-treated human immunoglobulin) in Japan. The product is an improved liquid formulation of the…
To read the full story
Related Article
- Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
BUSINESS
- Vital KSK’s Medleap Pivots to In-House Drug Filings, Eyes 2029 Launch
November 10, 2026
- Alfresa, Partners Seal Share Deal to Formalize Biosimilar JV
November 10, 2026
- Japan Ethical Drug Sales Rise 3.5% in September: Crecon
November 10, 2026
- Shionogi Grabs Japan Nod for Updated COVID Vaccine
November 10, 2026
- Kyorin Nabs Japan Rights to Edesa’s ARDS Drug
November 10, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…